ZS Pharma To Present Data From Phase 3 Trial Of ZS-9 As Late-Breaking Oral Presentation At 2014 American Society of Hypertension (ASH) Annual Scientific Meeting

ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that sub-group analysis data from a pivotal Phase 3 trial of ZS-9, an investigational treatment for hyperkalemia, will be presented as a late-breaking oral presentation at the 2014 American Society of Hypertension (ASH) Annual Scientific Meeting and Exposition at the New York Hilton Midtown in New York City.

Help employers find you! Check out all the jobs and post your resume.